USBio Logo

005487 Cabozantinib L-Malate Salt CAS: 849217-68-1

Specifications
References
CAS Number
849217-68-1
Grade
Highly Purified
Molecular Formula
C28H24FN3O5C4H6O5
Molecular Weight
635.59
EU Commodity Code
38220090
Shipping Temp
RT
Storage Temp
4°C
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (2S)-2-Hydroxybutanedioic Acid; Cabozantinib S-Malate; BMS-907351; XL-184; Cometriq

Cabozantinib is a small molecule C-Met modulator. Cabozantinib acts as a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis.

Cabozantinib, also known as XL184, is an orally bioavailable novel tysosine kinase inhibitor of c-MET and VEGF receptor 2 (VEGFR2). It inhibited MET and VEGFR2 with IC50 values of 1.3 nM and 35 pM, respectively. It also inhibited MET-activating kinase domain mutations Y1248H, D1246N, or K1262R with IC50 values of 3.8, 11.8, and 14.6 nM, respectively. It strongly inhibited several kinases that are implicated in tumor pathobiology including KIT, RET, AXL, TIE2, and FLT3 with IC50 values of 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively. In cellular assays, cabozantinib inhibited phosphorylation of MET, VEGFR2, KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 [micro]M, respectively. Cabozantinib inhibited tumor angiogenesis, tumor growth and metastasis in cancers with dysregulated MET and VEGFR signaling. Yakes F.M., et al "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth." Mol. Cancer Ther. 10: 2298-2308 (2011).
Treatment of RIP-Tag2 mice with cabozantinib eliminated approximately 80% of the vasculature of spontaneous pancreatic islet tumors over 7 days, reduced pericytes and empty basement membrane sleeves, resulted in widespread intratumoral hypoxia and tumor cell apoptosis, and delayed regrowth of the tumor vasculature after drug withdrawal. Importantly, it also inhibited invasiveness of primary tumors and reduced metastasis. You W.K., et al. "VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer." Cancer Res. 71: 4758-4768 (2011).
Cabozantinib is active in patients with medullary thyroid cancer and has an acceptable safety profile. Kurzrock R., et al. "Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer." J. Clin. Oncol. 29: 2660-2666 (2011).
Cabozantinib 40 mg daily was associated with a high rate of bone scan response and better tolerability in patients with metastatic castration-resistant prostate cancer when compared with previously reported results for cabozantinib 100 mg daily. Lee R.J., et al. "A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases." Clin Cancer Res. 19: 3088-3094 (2013).
Cabozantinib demonstrated activity in patients with metastatic melanoma in a phase 2 randomized discontinuation trial. Gordon M.S. etal. "Activity of Cabozantinib (XL184) in Metastatic Melanoma: Results From a Phase 2 Randomized Discontinuation Trial (RDT)." http://www.exelixis.com/sites/default/files/2012-06-02_Gordon%20Melanoma_ASCO%202012%20FINAL_poster_8531.pdf
Cabozantinib was active in patients with metastatic non-small cell lung cancer (NSCLC) in a phase 2 randomized discontinuation trial. Hellerstedt B.A. et al. "Activity of Cabozantinib (XL184) in Metastatic NSCLC: Results From a Phase 2 Randomized Discontinuation Trial (RDT)." http://www.exelixis.com/sites/default/files/2012-06-05_Hellerstedt%20NSCLC_ASCO%202012_FINAL_poster_7514.pdf response to anthracycline therapy." Cell Cycle 11: 2747-2755 (2012).
Appearance
White to off-white, cystalline powder
Purity
≥99% (HPLC, TLC)
Melting Point
As reported
Solubility
DMSO
Method for Determining Identity
NMR (DMSO-d6) and MS
Storage and Stability
May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Purity
≥99% (HPLC, TLC)
Form
Off-White Solid
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
Camp, R., et al.: Cancer, 86, 2259
USBio References
No references available
Pricing
Order
Proceed to Checkout
Cart Summary
ProductSizeListYour PriceQtyExt Price
Subtotal:Subtotal:
Subtotal:Subtotal:
Total Coupon Savings:Total Coupon Savings:()
Your cart is currently empty.
- Coupon Code
Recently Viewed
  • Contact Us

    Visit our technical library or contact our support staff to answer your questions.

    Telephone:
    1-800-520-3011

    Library | Contact

    Distributors

    For customers outside of the United States, please use one of our many distributors.

    View Distributors

    Payment Methods

    We accept the following payment methods as well as pay-by-invoice.

    MasterCard Visa PayPal
    © 2023-2024 United States Biological - All Rights Reserved